Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.

Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017

5.278 Aufrufe

Veröffentlicht am

Preparedness for and response to meningococcal outbreaks: preliminary results of a Canadian Immunization Research Network (CIRN) randomized controlled trial of two schedules of 4CMenB vaccine in adolescents and young adults.
https://www.meningitis.org/mrf-conference-2017

Veröffentlicht in: Gesundheit & Medizin
  • I’ve personally never heard of companies who can produce a paper for you until word got around among my college groupmates. My professor asked me to write a research paper based on a field I have no idea about. My research skills are also very poor. So, I thought I’d give it a try. I chose a writer who matched my writing style and fulfilled every requirement I proposed. I turned my paper in and I actually got a good grade. I highly recommend ⇒ www.HelpWriting.net ⇐
       Antworten 
    Sind Sie sicher, dass Sie …  Ja  Nein
    Ihre Nachricht erscheint hier
  • Did u try to use external powers for studying? Like ⇒ www.WritePaper.info ⇐ ? They helped me a lot once.
       Antworten 
    Sind Sie sicher, dass Sie …  Ja  Nein
    Ihre Nachricht erscheint hier
  • Dating for everyone is here: ❤❤❤ http://bit.ly/2Qu6Caa ❤❤❤
       Antworten 
    Sind Sie sicher, dass Sie …  Ja  Nein
    Ihre Nachricht erscheint hier
  • Follow the link, new dating source: ❤❤❤ http://bit.ly/2Qu6Caa ❤❤❤
       Antworten 
    Sind Sie sicher, dass Sie …  Ja  Nein
    Ihre Nachricht erscheint hier
  • Gehören Sie zu den Ersten, denen das gefällt!

Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017

  1. 1. Preparedness for and response to meningococcal outbreaks: preliminary results of a Canadian Immunization Research Network (CIRN) randomized controlled trial of two schedules of 4CMenB vaccine in adolescents and young adults JM Langley, S Gantt, C Quach,, J Bettinger, SA Halperin, J Mutch, S McNeil, B. Ward, D. MacKinnon-CameronL Ye, K Marty, D. Scheifele, J Alcantara and CIRN Funded by the Canadian Institutes of Health Research and the Public Health Agency of Canada
  2. 2. Rationale  Meningococcus B most common cause of IMD in Canada  Institutional outbreaks are rare (<5% of cases) but create public health crises  MenB vaccine in Canada:  4CMenB (Bexsero®, GlaxoSmithKline) authorized for persons 2 months -17 years in Dec 2013  Not part of routine immunization schedule  limited data on safety and immunogenicity in persons >17 years, or on various dosing schedules  Emergency vaccination programs used for outbreaks  Quebec 2014 for 2 month - 20 year olds  Acadia University 2015
  3. 3. Methods  Enrolment in first term of academic year (Sept 2015- April 2016) over 4 to 6 weeks  Eligibility  17-25 years of age, healthy  attending school  randomized, controlled, observer-blinded trial  Compare safety and immunogenicity of two 4CMenB vaccination schedules: Accelerated (0, 21 days) vs. Standard schedule (0, 60 days)
  4. 4. Solicited Local Events: pain most common, with 4CMenB
  5. 5. Solicited General Adverse Events: Muscles aches, drowsiness most common; with 4CMenB
  6. 6. Immunogenicity outcomes  Human Serum Bactericidal Titres (hSBA) on days 0, 21, 42, 81,180 using MenB strains 5/99, H44/76 and NZ98/254 (assays using epidemic strains pending)  Geometric Mean Titers (GMTs)  Reverse Cumulative Distribution graphs
  7. 7. NZ98/254 H44/765/99 GMTs by strain, days 0 to 180
  8. 8. hSBA Titers: Reverse Cumulative Distribution Day 21 Day 180
  9. 9. Conclusions: RCT of 0,21 vs. 0,60 day 4CMenB schedule in 17-25 year old students  Capacity building for rapid trials: conducted rapidly in 1st term of academic year at 3 sites, >99% retention at six months  Safety: reactogenicity greater in 4CMenB recipients: injection site pain in >96%, muscles aches and drowsiness in ~50% (tolerability outcomes pending)  Immunogenicity: protective titers present in all 4CMenB recipients 21 days after first dose, sustained in >90 % at Day 180 (hSBA to outbreak strains pending)  An accelerated 4CMenB schedule (0, 21 days) could be used to control outbreaks in adolescents/young adults

×